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Abstract
Background: Hesperetin was reported to selectively inhibit phosphodiesterase 4 (PDE4). While hesperetin-7,3’-O-
dimethylether (HDME) is a synthetic liposoluble hesperetin. Therefore, we were interested in investigating its
selectivity on PDE4 and binding ability on high-affinity rolipram-binding sites (HARBs) in vitro, and its effects on
ovalbumin-induced airway hyperresponsiveness in vivo, and clarifying its potential for treating asthma and chronic
obstructive pulmonary disease (COPD).
Methods: PDE1~5 activities were measured using a two-step procedure. The binding of HDME on high-affinity
rolipram-binding sites was determined by replacing 2 nM [
3H]-rolipram. AHR was assessed using the FlexiVent
system and barometric plethysmography. Inflammatory cells were counted using a hemocytometer. Cytokines were
determined using mouse T helper (Th)1/Th2 cytokine CBA kits, and total immunoglobulin (Ig)E or IgG2a levels were
done using ELISA method. Xylazine (10 mg/kg)/ketamine (70 mg/kg)-induced anesthesia was performed.
Results: HDME revealed selective phosphodiesterase 4 (PDE4) inhibition with a therapeutic (PDE4H/PDE4L) ratio of
35.5 in vitro. In vivo, HDME (3~30 μmol/kg, orally (p.o.)) dose-dependently and significantly attenuated the airway
resistance (RL) and increased lung dynamic compliance (Cdyn), and decreased enhanced pause (Penh) values
induced by methacholine in sensitized and challenged mice. It also significantly suppressed the increases in the
numbers of total inflammatory cells, macrophages, lymphocytes, neutrophils, and eosinophils, and levels of
cytokines, including interleukin (IL)-2, IL-4, IL-5, interferon-g, and tumor necrosis factor-a in bronchoalveolar lavage
fluid (BALF) of these mice. In addition, HDME (3~30 μmol/kg, p.o.) dose-dependently and significantly suppressed
total and ovalbumin-specific immunoglobulin (Ig)E levels in the BALF and serum, and enhanced IgG2a level in the
serum of these mice.
Conclusions: HDME exerted anti-inflammatory effects, including suppression of AHR, and reduced expressions of
inflammatory cells and cytokines in this murine model, which appears to be suitable for studying the effects of
drugs on atypical asthma and COPD, and for screening those on typical asthma. However, HDME did not influnce
xylazine/ketamine-induced anesthesia. Thus HDME may have the potential for use in treating typical and atypical
asthma, and COPD.
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Phosphodiesterases (PDEs) are classified according to
their primary protein and complementary (c)DNA
sequences, co-factors, substrate specificities, and phar-
macological roles. It is now known that PDEs comprise
at least 11 distinct enzyme families that hydrolyze ade-
nosine 3’,5’ cyclic monophosphate (cAMP) and/or gua-
nosine 3’,5’ cyclic monophosphate (cGMP) [1]. PDE1~5
isozymes, which are calcium/calmodulin dependent
(PDE1), cGMP stimulated (PDE2), cGMP inhibited
(PDE3), cAMP specific (PDE4), and cGMP specific
(PDE5), were found to be present in the canine trachea
[2], guinea pig lungs [3], and human bronchi [4]. PDE3
and PDE4 were identified in the guinea pig airway [5],
but other isozymes might also be present. PDE4 may
adopt two different conformations which have high
(PDE4H) and low (PDE4L) affinities for rolipram, respec-
tively. In general, it is believed that inhibition of PDE4H
is associated with adverse responses, such as nausea,
vomiting, and gastric hypersecretion, while inhibition of
PDE4L is associated with anti-inflammatory and bronch-
odilating effects. Therefore the therapeutic ratio of
selective PDE4 inhibitors for use in treating asthma and
chronic obstructive pulmonary disease (COPD) is
defined as the PDE4H/PDE4L ratio [6,7].
Hesperetin (5,7,3’-trihydroxy-4’-methoxyflavanone),
one of the most-common flavonoids in Citrus,i sa l s o
present in herbal medicine as glycosides. For example,
hesperidin and neohesperidin are abundantly present in
the fruit peel of Citrus aurantium L. (Rutaceae), a well-
known traditional Chinese medicine (TCM) called
“Chen-Pi"; they are used as an expectorant and stomach
tonic, and contain vitamin P, a remedy for preventing
capillary fragility and hypertension [8]. These glycosides
are easily hydrolyzed by glycosidase to form hesperetin
after ingestion. Based on lung histopathological studies
using hematoxylin and eosin and alcian blue-periodic
acid-Schiff staining, hesperidin was recently reported to
inhibit inflammatory cell infiltration and mucus hyperse-
cretion compared with the ovalbumin-induced group of
mice in a murine model of asthma [9]. Men with higher
hesperetin intake have lower mortality from cerebrovas-
cular disease and lung cancer, and lower incidences of
asthma [10]. Because hesperetin was reported to selec-
tively inhibit PDE4 activity [11], it was used as a lead
compound to synthesize hesperetin-7,3’-O-dimethylether
(HDME), a more-liposoluble derivative of hesperetin.
Therefore, we were interested in investigating the
PDE4H/PDE4L ratio and suppressive effects of HDME
on ovalbumin (OVA)-induced airway hyperresponsive-
ness (AHR), and clarifying its potential for treating
asthma and COPD. Although both asthma and COPD
are associated with an underlying chronic inflammation
of the airways, there are important differences with
regard to the inflammatory cells and mediators involved.
The key inflammatory cells in COPD are macrophages,
CD8+ T-lymphocytes and neutrophils. Macrophages are
strongly increased in the airway lumen, lung parench-
yma and bronchoalveolar lavage fluid. In the airway wall
and lung parenchyma, the ratio of CD8+/CD4+ T-lym-
phocytes increases. Neutrophils are increased in sputum
and their number grows with the progression of the dis-
ease. In contrast, the key inflammatory cells in asthma
are mast cells, eosinophils and CD4+ T-lymphocytes.
Both diseases are sensitive to steroids. However, COPD
shows a limited response to inhaled corticosteroids as
compared to the efficacy achieved in asthma. Owing to
the side effects of steroids, other therapeutics such as
selective PDE4 or dual PDE3/4 inhibitors are develop-
ing. However, these developing inhibitors are also lim-
ited for the use of asthma and COPD in clinic because
of their emetic side effect. This side effect can be easily
assessed in non-vomiting species, such as rats or mice,
in which selective PDE4 inhibitors reduce the duration
of xylazine/ketamine-induced anesthesia [12,13].
Materials and methods
Reagents and animals
HDME (mol wt., 330.27) was synthesized according to a
previous method [14] in our laboratory and identified by
spectral methods, including ultraviolet, infrared, mass
spectroscopy, and nuclear magnetic resonance spectro-
scopic techniques. The purity of the compound
exceeded 98% as determined by high-performance liquid
chromatography. OVA, methacholine (MCh), aluminum
sulfate hexadecahydrate, dimethylsulfoxide (DMSO),
chloralose, urethane, Tris-HCl, Bis-Tris, benzamidine,
phenylmethanesulfonyl fluoride (PMSF), d,l-dithiothrei-
tol, polyethyleneimine, ethylenediaminetetraacetic acid
(EDTA), bovine serum albumin (BSA), cAMP, cGMP,
calmodulin, Dowex resin, Crotalus atrox snake venom,
xylazine, and ketamine were purchased from Sigma
Chemical (St. Louis, MO, USA). Vinpocetine, erythro-9-
(2-hydroxy-3-nonyl)-adenine HCl (EHNA), milrinone, 4-
(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (Ro 20-
1724), and Zaprinast were purchased from Biomol (Ply-
mouth Meeting, PA, USA). Freund’s adjuvant (Mycobac-
terium butyricum)w a sp u r c h a s e df r o mP i e r c e
Biotechnology (Rockford, IL, USA). Mouse Th1/Th2
cytokine CBA kits, and mouse IgE enzyme-linked
immunosorbent assay (ELISA) sets were purchased from
Pharmingen (San Diego, CA, USA). Ethyl alcohol and
polyethylene glycol (PEG) 400 were purchased from
Merck (Darmstadt, Germany). [
3H]-cAMP, [
3H]-cGMP,
and [methyl-
3H]-rolipram were purchased from Amer-
sham Pharmacia Biotech (Buckinghamshire, UK). Other
reagents, such as CaCl2, MgCl2,a n dN a C l ,w e r eo fa n a -
lytical grade. HDME and Ro 20-1724 were dissolved in
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cle, a mixture of DMSO: ethyl alcohol: PEG 400: saline
(0.5: 0.5: 1: 8, v/v) used in vivo studies had no abnormal
behavior in mice after oral administration. Other
reagents were dissolved in distilled water.
Male Hartley guinea pigs (500~600 g) and female
BABL/c mice at 8~12 weeks old were purchased from
the Animal Center of the National Science Council (Tai-
pei, Taiwan), and housed in ordinary cages at 22 ± 1°C
with a humidity of 50%~60% under a constant 12/12-h
light/dark cycle and provided with food and water ad
libitum. Under a protocol approved by the Animal Care
and Use Committee of Taipei Medical University, the
following in vivo and in vitro experiments were
performed.
Competitive inhibition of PDE1, PDE3, and PDE4 activities
Activities of PDE1~5 in the homogenate of guinea pig
lungs or hearts were measured by a two-step procedure
according to the previous method [15], using cAMP
with [
3H]-cAMP or cGMP with [
3H]-cGMP as sub-
strates. In the Lineweaver-Burk analysis, the reaction
mixture contained 10 μl of vehicle or inhibitors, at var-
ious concentrations of HDME or selective PDE1, PDE3,
and PDE4 inhibitors, such as vinpocetine [16], milrinone
[17], and Ro 20-1724 [18] as reference drugs. The
reagents and homogenate were mixed on ice, and the
reaction was initiated by transferring the mixture to a
water bath at 37°C. Following a 30-min incubation, the
reaction was stopped by transferring the reaction vessel
to a bath of boiling water for 3 min. After cooling on
ice, 20 μl of a 1 mg/ml solution of Crotalus atrox snake
venom was added to the reaction mixture, and the mix-
ture was incubated at 37°C for 10 min. Unreacted [
3H]-
cAMP or [
3H]-cGMP was removed by the addition of
500 μl of a 1-in-1 Tris-HCl (40 mM) buffer suspension
of Dowex resin (1 × 8-200) with incubation on ice for
30 min. Each tube was then centrifuged at 3700 g for 2
min, and 150 μl of the supernatant was removed for
liquid scintillation counting. Less than 10% of the tri-
tiated cyclic nucleotide was hydrolyzed in this assay.
The total protein in each fraction used was assayed
according to a previous method [19]. PDE activities are
reported as nmol/mg/min.
Determination of PDE4H values
When the above-mentioned guinea pigs were sacrificed,
the whole brains were removed and homogenized with a
glass/Teflon homogenizer (Glas-Col, Terre Haute, IN,
USA) in 10 volumes of cold medium (pH 6.5) contain-
ing 20 mM Bis-Tris, 2 mM benzamidine, 2 mM EDTA,
50 mM sodium chloride, 0.1 mM PMSF, and 1 mM
dithiothreitol. At 4°C, the homogenate was centrifuged
at 170 g for 5 min to remove connective tissues and
blood vessels. The suspended homogenate was then re-
centrifuged at 40,000 g for 30 min to separate the cyto-
solic and particulate portions. The particulate portion
was re-suspended in a suspension at a concentration of
400 mg/ml (wet weight/volume), after washing three
times with homogenizing buffer. The particulate portion
mainly consisted of cell membranes. The binding ability
of HDME (3~300 μM) to high-affinity rolipram-binding
sites (HARBSs) of guinea pig brain cell membranes was
determined by replacing 2 nM [
3H]-rolipram in a reac-
tion buffer at 30°C for 1 h, according to the method
described by previous investigators [20,21] and modified
by us. Briefly, the reaction buffer consisted of 50 mM
Tris-HCl and 5 mM MgCl2 (pH 7.5). The total volume
of the reaction mixture was 25 μl, consisting of 10 μlo f
the particulate suspension, 10 μlo f[
3H]-rolipram, and 5
μl of HDME or Ro 20-1724 (1~10,000 nM), a reference
drug. After 1 h, the reaction was terminated by moving
the reaction vessel into crushed ice. Then the reaction
mixture was transferred onto Whatman GF/B glass-fiber
filters, which were soaked in a 0.3% polyethyleneimine
solution in a mini-funnel. The reaction mixture was fil-
tered by centrifugation at 90 g for 10 s, and the filtrate
was collected into a 1.5-ml Eppendorf tube with the top
adapted to the outlet of the mini-funnel. The filters
were washed with 300 μl of reaction buffer three times
each in the same way, and transferred into 2 ml of cock-
tail for radiation counting (total binding) using a b-scin-
tillation counter (Beckman, Fullerton, CA, USA). Non-
specific binding, which was defined in the presence of
10 μM Ro 20-1724, was subtracted from total binding
to yield specific binding. Effective concentration (EC50)
values of HDME and Ro 20-1724, at which a half of the
[
3H]-rolipram that was bound onto HARBSs of cell
membranes was displaced, were defined as PDE4H
values, and these were related to any adverse effects,
such as nausea, vomiting, and gastric hypersecretion [7].
Airway hyperresponsiveness (AHR) in vivo
According to the schedule (Figure 1), ten female BABL/
c mice in each group were sensitized by an intraperito-
neal (i.p.) injection of 20 μgo fO V Ae m u l s i f i e di n2 . 2 5
mg of an aluminum hydroxide gel, prepared from alumi-
num sulfate hexadecahydrate, in a total volume of 100
μl on days 0 and 14. On day 21, these mice were
injected with (i.p.) 100 μlo fam i x t u r eo f1 %O V Aa n d
Freund’s complete adjuvant (1:1). Mice were challenged
via t h ea i r w a yu s i n g1 %O V Ai ns a l i n ef o r3 0m i no n
days 28, 29, and 30 by ultrasonic nebulization. After the
last of OVA challenges [22], AHR was assessed on day
32 (48 h after 1% OVA provocation) in each group.
Each group of mice was orally (p.o.) administered the
vehicle (control) or 3~30 μmol/kg of HDME 2 h before
and 6 and 24 h after OVA provocation. For comparison,
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of 1% OVA (non-challenged). The vehicle, a mixture of
DMSO: ethyl alcohol: PEG 400: saline (0.5: 0.5: 1: 8, v/
v), or HDME was administered (p.o.) at a volume of
0.01 ml/g of body weight. AHR was assessed using two
methods: (1) in anesthetized ventilated mice, AHR was
assessed as previously described [23] by measuring
changes in the airway resistance (RL, cmH2O/ml/sec)
and lung dynamic compliance (Cdyn,m l / c m H 2O) after
challenge with aerosolized methacholine (MCh, 0.78~25
mg/ml) using the FlexiVent system (SCIREQ, Montreal,
Quebec, Canada). Anesthetized (urethane 600 mg/kg
and chloralose 120 mg/kg, i.p.), tracheostomized (stain-
less-steel cannula, 18 G) mice were mechanically venti-
lated (at 150 breaths/min, with a tidal volume of 10 ml/
kg, positive end-expiratory pressure of 3 cmH2O). (2) in
unrestrained animals by barometric plethysmography
[24] using a whole-body plethysmograph (WBP) and
analyzed using software of Life Science Suite P3 Analysis
Modules (Gould, LDS Test and Measurement LLC, Val-
ley View, OH, USA). Mice were placed into the main
chamber of the WBP, and the baseline enhanced pause
(Penh) value was determined. Then mice were first nebu-
lized with phosphate-buffered saline (PBS), and subse-
quently with increasing doses (6.25~50 mg/ml) of MCh
for 3 min for each nebulization, followed by readings of
breathing parameters for 3 min after each nebulization
to determine Penh values.
Inflammatory cells, cytokines and immunoglobulins
Twenty-four hours after Penh determination, these mice
were anesthetized with pentobarbital (50 mg/kg, i.p.),
and the lungs were lavaged via a tracheal tube with PBS
(1 × 1.0 ml, 37°C). After lavage, blood was collected
from the jugular vein and allowed to sit so that it would
coagulate. The collected bronchoalveolar lavage fluid
( B A L F )a n dc o a g u l a t e db l o o dw e r er e s p e c t i v e l y
centrifuged at 630 g for 7 min and at 3700 g for 10 min
at 4°C. After centrifugation, the BALF and serum super-
natants were stored at -20°C until determination of
cytokines, including interleukin (IL)-2, IL-4, IL-5, tumor
necrosis factor (TNF)-a, and interferon (IFN)-g by flow
cytometric methods [25] using mouse T helper (Th)1/
Th2 cytokine CBA kits, and of total immunoglobulin
(Ig)E or IgG2a using ELISA kits (Pharmingen, San
Diego, CA, USA) according to the respective recom-
mendations of the manufacturers. OVA-specific IgE was
measured as described previously [26]. Wells were
coated with 100 μlo fO V A( 2 0μg/ml) instead of the
capture antibody. Levels are expressed in arbitrary units,
where 1 arbitrary unit equals the optical density of the
sample divided by the optical density of unchallenged
mouse serum or BALF (standard). The BALF pellet was
resuspended in ACK lysing buffer (1.658 g NH4Cl, 0.2 g
KHCO3 and 1.44 mg EDTA in 200 ml of water) to lyse
the residual erythrocytes in each sample. The number of
inflammatory cells was counted using a hemocytometer
(Hausser Scientific, Horsham, PA, USA). Cytospun
slides were stained and differentiated in a blinded fash-
ion by counting at least 100 cells under light micro-
scopy. All undetectable data (< 1 pg/ml) of cytokines
were taken as 0 pg/ml.
Xylazine/ketamine-induced anesthesia
According to a previously described method [13] and
modified by us, HDME (10~100 μmol/kg, subcuta-
neously (s.c.)) or Ro 20-1724 (0.01~1 μmol/kg, s.c.), a
reference drug, was respectively injected into 8~12-
week-old female BALB/c mice 1 or 0.25 h prior to an i.
p. injection of xylazine (10 mg/kg)/ketamine (70 mg/kg).
The vehicle (control) for HDME or Ro 20-1724 was a
mixture of DMSO: ethyl alcohol: PEG 400: saline (0.5:
0.5: 1: 8, v/v). After loss of the righting reflex (i.e., when
a mouse remained on its back and no longer
Figure 1 The schedule of sensitization, challenge and drug administration in mice. AHR, airway hyperresponsiveness; Al(OH)3, aluminum
hydroxide gel; HDME, hesperetin-7,3’-O-dimethylether.
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duration of anesthesia was measured until its return as
the endpoint [13].
Statistical methods
A l lv a l u e sa r eg i v e na st h em e a n s±S E M .D i f f e r e n c e s
among values were statistically calculated by one-way
analysis of variance (ANOVA), and then determined by
Dunnett’s test. The difference between two values, how-
ever, was determined by the use of Student’s t-test. Dif-
ferences with p < 0.05 were considered statistically
significant.
Results
Competitive inhibition of PDE1, PDE3, and PDE4 activities
HDME did not inhibit PDE2 or PDE5 activities (IC50
value > 100 μM), but it concentration-dependently
inhibited PDE1, PDE3, and PDE4 activities with respec-
tive IC50 values of 22.1 ± 6.4 (n = 4), 24.6 ± 3.5 (n =4 ) ,
and 3.0 ± 0.9 μM( n = 4) (Figure 2A-C). Similarly, the
reference drugs, vinpocetin, milrinone, and Ro 20-1724,
inhibited these enzymes with respective IC50 values of
42.3 ± 5.8 (n = 6), 2.5 ± 1.6 (n =5 ) ,a n d4 . 3±2 . 1μM
(n =4 )( F i g u r e2 D - F ) .T h eI C 50 value of HDME for
PDE4 inhibition was significantly less than those for
PDE1 and PDE3 inhibition. According to the Linewea-
ver-Burk analysis, HDME (1~10 μM) and Ro 20-1724
(1~10 μM) competitively inhibited PDE4 activity (Figure
3), with calculated dissociation constant for inhibitory
binding (Ki) values of 2.1 ± 1.3 (n = 4) and 8.1 ± 2.4 (n
=4 )μM, respectively (Figure 3 inset).
PDE4H/PDE4L ratios
HDME (3~300 μM), similar to Ro 20-1724 (1~10000
nM), concentration-dependently displaced 2 nM [
3H]-
rolipram binding on HARBSs of guinea pig brain cell
membranes (Figure 4A, B). The respective EC50
(PDE4H) values of HDME and Ro 20-1724 for displacing
[
3H]-rolipram binding were 106.6 ± 39.5 (n =6 )μM and
87.0 ± 29.0 (n =4 )n M .H o w e v e r ,t h eI C 50 values for
inhibiting PDE4 catalytic activity of HDME and Ro 20-
1724 were taken to be PDE4L values, which respectively
were 3.0 and 8.7 μM. Thus, the PDE4H/PDE4L ratios of
HDME and Ro 20-1724 were 35.5 and 0.01, respectively.
Figure 2 Log concentration-inhibition curves. Log concentration-
inhibition curves of HDME (A-C) and reference drugs (D-F) on PDE1
(A, D), PDE3 (B, E), and PDE4 (C, F) activities.
Figure 3 Inhibition of PDE4-induced cAMP hydrolysis by HDME
(A) and Ro 20-1724 (B). Activities of PDE4 in the presence of
various concentrations of HDME or Ro 20-1724, and the substrate
(cAMP) were plotted according to a Lineweaver-Burk analysis. Ki was
determined from the equation of the apparent Km as a function of
the inhibitor concentration (inset). Each value represents the mean
± SEM (n = 3).
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RL values at the baseline for the control (vehicle), non-
challenged, and 3, 10, and 30 μmol/kg HDME groups
were 1.03 ± 0.03, 1.04 ± 0.05, 1.06 ± 0.05, 1.08 ± 0.06,
and 1.09 ± 0.07 cmH2O/ml/s, respectively, and these
values did not significantly differ from each other. RL
values of PBS nebulization for each group were 1.05 ±
0.04, 1.06 ± 0.05, 1.10 ± 0.07, 1.06 ± 0.04, and 1.07 ±
0.06 cmH2O/ml/s, respectively, which also did not sig-
nificantly differ from each other. Administration of neb-
ulized PBS did not affect the RL values of the baseline in
each group. However, MCh (6.25~25 mg/ml) concentra-
tion-dependently and significantly increased RL values
(Figure 5A), and decreased Cdyn values (Figure 5B) in
the control sensitized and challenged group compared
to the non-challenged group. HDME (3~30 μmol/kg, p.
o.) significantly suppressed these changes (Figure 5).
Penh values at the baseline for the control (vehicle),
non-challenged, and 3, 10, and 30 μmol/kg HDME
groups were 2.32 ± 0.04, 2.41 ± 0.05, 2.45 ± 0.04, 2.36 ±
0.05, and 2.43 ± 0.03, respectively, and these values did
not significantly differ from each other. Penh values with
PBS nebulization for each group were 2.42 ± 0.05, 2.41
± 0.04, 2.43 ± 0.05, 2.38 ± 0.06, and 2.44 ± 0.06, respec-
tively, which also did not significantly differ from each
other. Administration of nebulized PBS did not affect
the Penh value of the baseline in each group. However,
MCh (6.25~50 mg/ml) concentration-dependently
increased Penh values from 1-fold with PBS exposure to
1.85 ± 0.20-fold in control sensitized and challenged
mice (Figure 5A). Penh values of MCh at 25 and 50 mg/
Figure 4 Displacement of [
3H]-rolipram by HDME. Displacement
of [
3H]-rolipram by HDME (A) and Ro 20-1724 (B) in high-affinity
rolipram binding sites of guinea pig brain particulate. Each value
represents the mean ± SEM. The experimental number for HDME at
each concentration was 6, and for Ro 20-1724 was 4. Figure 5 Effects of HDME (3~30 µmol/kg, p.o.) on airway
resistance. Effects of HDME (3~30 µmol/kg, p.o.) on airway
resistance (RL, A) and lung dynamic compliance (Cdyn,B )i n
sensitized and challenged mice which received aerosolized
methacholine (MCh, 0.78~25 mg/ml) 2 days after primary allergen
challenge.
### P< 0.001, compared to the non-challenged group. * p
< 0.05, ** p< 0.01 and *** p< 0.001, compared to the control
(vehicle) group. The number of mice in each group was 10. PBS,
phosphate-buffered saline.
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nificantly enhanced compared to those in non-chal-
lenged mice. HDME (3~30 μmol/kg, p.o.) dose-
dependently and significantly attenuated the enhance-
ment of Penh values induced by 25 and 50 mg/ml MCh
(Figure 6A).
Suppression of inflammatory cells and cytokines in the
BALF
In this special animal model, the number of neutrophils
in the bronchoalveolar lavage fluid of control sensitized
and challenged mice was significantly more than that of
eosinophils. The numbers of total inflammatory cells,
macrophages, lymphocytes, neutrophils, and eosinophils
from the BALF of control sensitized and challenged
mice significantly increased compared to those of non-
challenged mice (Figure 6B). HDME (3~30 μmol/kg, p.
o.) significantly suppressed the increases in numbers of
total inflammatory cells, macrophages, lymphocytes,
neutrophils, and eosinophils (Figure 6B). Noticeably, the
numbers of eosinophils were abolished by HDME at
various doses used.
Compared to those in non-challenged mice, levels of
cytokines, such as IL-2, IL-4, IL-5, IFN-g, and TNF-a,i n
the BALF of control sensitized and challenged mice sig-
nificantly increased (Figure 6C). HDME (3~30 μmol/kg,
p.o.) also significantly suppressed increases in levels of
IL-2, IL-4, IL-5, and TNF-a, but enhanced the level of
IFN-g at 30 μmol/kg (Figure 6C).
Suppression of IgE and IgG2a in the serum and BALF
The level of total IgG2a in the serum of control sensi-
tized and challenged mice was significantly supressed
compared to that of non-challenged mice. HDME (3~30
μmol/kg, p.o.) dose-dependently and significantly
enhanced this supression (Figure 7A). However, levels of
total and OVA-specific IgE in the BALF and serum of
control sensitized and challenged mice were significantly
enhanced compared to those of non-challenged mice.
HDME (3~30 μmol/kg, p.o.) dose-dependently and sig-
nificantly suppressed these enhancements (Figure 7B-E).
No effect on xylazine/ketamine-induced anesthesia
The durations of xylazine/ketamine-induced anesthesia
in control (vehicle) mice for the rolipram- and HDME-
treated groups were 22.0 ± 3.0 (n = 10) and 22.4 ± 1.5
min (n = 10), respectively. Rolipram (0.01~1 μmol/kg, s.
c.) dose-dependently shortened the duration, and at
doses of 0.1 and 1 μmol/kg (s.c.) significantly shortened
the duration (Figure 8A). In contrast, HDME (10~100
μmol/kg, s.c.) did not significantly influnce the duration
(Figure 8B).
Discussion
Allergic asthma (type-I allergic airway disease) is a
chronic respiratory disease characterized by AHR,
mucus hypersecretion, bronchial inflammation, and ele-
vated IgE levels. Th2 cells, together with other inflam-
matory cells such as eosinophils, B cells, and mast cells
are thought to play critical roles in the initiation, devel-
opment, and chronicity of this disease [27]. This clinical
Figure 6 Effects of HDME (3~30 μmol/kg, p.o.) on the
enhanced pause (Penh). Effects of HDME (3~30 μmol/kg, p.o.) on
the enhanced pause (Penh) (A), inflammatory cells (B), and cytokines
(C) in sensitized mice which received aerosolized methacholine
(6.25~50 mg/ml) 2 days after primary allergen challenge.
# p< 0.05,
## p< 0.01, and
### p< 0.001, compared to the non-challenged
group. * p< 0.05, ** p< 0.01, and *** p< 0.001, compared to the
control (vehicle) group. The number of mice in each group was 10.
Total, total cells; Mac, macrophages; Lym, lymphocytes; Neu,
neutrophils; Eos, eosinophils; IL, interleukin; IFN, interferon; TNF,
tumor necrosis factor.
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more severe phenotype found in a considerable propor-
tion of asthmatics who have increased neutrophil cell
counts in the airway as a distinguishing trait. Neutrophi-
lic inflammation is a hallmark of another type of allergic
airway pathology, hypersensitivity pneumonitis. Consid-
ered as an immune counterpart of asthma, hypersensi-
tivity pneumonitis is a prototypical type-III allergic
inflammatory reaction involving the alveoli and lung
interstitium, steered by Th1 cells and IgG and, in its
chronic form, accompanied by fibrosis [28]. Thus, this
animal model appears to be suitable for studying the
effects of drugs on the atypical asthma and COPD, and
for screening those on typical asthma. One hypothesis
emphasizes an imbalance in Th cell populations favoring
expression of Th2 over Th1 cells in typical asthma.
Cytokines released from Th2 cells are IL-4, IL-5, IL-6,
IL-9, and IL-13, and those from Th1 cells are IL-2, IL-
12, IFN-g,a n dT N F - a [29,30]. In the present results,
HDME (3~30 μmol/kg, p.o.) significantly decreased RL
(Figure 5A), and increased Cdyn (Figure 5B), and also
attenuated Penh values (Figure 6A) suggesting that it sig-
nificantly suppresses AHR. The numbers of all types of
inflammatory cells examined, including total inflamma-
tory cells, macrophages, lymphocytes, neutrophils, and
eosinophils in the BALF of sensitized and challenged
mice were reduced by HDME (3~30 μmol/kg, p.o.) (Fig-
ure 6B). It is well known that after oral administration
and digestion of hesperidin, a flavanone glycoside
Figure 8 Effects of subcutaneously administered rolipram (A)
and HDME (B). Effects of subcutaneously administered rolipram (A)
and HDME (B) on the duration of xylazine (10 mg/kg, i.p.)/ketamine
(70 mg/kg, i.p.)-induced anesthesia in mice. Rolipram was
administered 0.25 h and HDME 1 h before anesthesia. ** p< 0.01,
*** p< 0.001, compared to the vehicle (control). Each value
represents the mean ± SEM. The number of mice in each group
was 10.
Figure 7 Effects of HDME (3~30 μmol/kg, p.o.) on total IgG2a
and IgE. Effects of HDME (3~30 μmol/kg, p.o.) on total IgG2a (A),
total IgE (B) and ovalbumin-specific IgE (C) levels in the serum and
bronchial alveolar lavage fluid (D, E) of sensitized mice which had
received aerosolized methacholine (6.25~50 mg/ml) 2 days after
primary allergen challenge.
# p< 0.05,
## p< 0.01 and
### p< 0.001,
compared to the non-challenged group. * p< 0.05, ** p< 0.01 and
*** p< 0.001, compared to the control (vehicle) group. Each value
represents the mean ± SEM. The number of mice in each group
was 10.
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charide rutinose, forms hesperetin. Similarly, hesperetin
is also formed by demethylation of HDME after oral
administration. However, whether the effects of HDME
on lung tissue are similar to those of hesperidin [9]
needs to be further investigated. It also suppressed levels
of IL-2, IL-4, IL-5, and TNF-a, but significantly
enhanced the level of IFN-g (Figure 6C). These results
suggest that HDME fully suppresses Th2 cells and par-
tially activates Th1 cells, and ameliorates this imbalance
occurred in typical asthma. However, this partial activa-
tion of Th1 cells may offset, at least in a part, some
anti-inflammatory effects of HDME, by which IL-2 and
TNF-a released from Th1 cells were reduced. However,
the number of neutrophils was significantly reduced by
HDME, suggesting that it may have a benefit for treat-
ing atypical asthma. Similarly, the numbers of macro-
phages and neutrophils were reduced by HDME,
suggesting that it may ameliorate COPD too.
IL-4 and IL-13 were shown to induce AHR in mouse
asthma models [31,32]. IL-4 has three primary effects.
First, IL-4 promotes B cell differentiation to plasma cells
that secrete antigen-specific IgE antibodies. Second, IL-4
promotes mast cell proliferation. Third, increased IL-4
upregulates endothelial cell expression of adhesion
molecules for eosinophils [33]. IL-5 mobilizes and acti-
vates eosinophils, leading to the release of a major basic
protein, cysteinyl-leukotriene, and eosinophil peroxidase
that contribute to tissue damage and AHR [32,34].
Phosphoinositide 3-kinase δ (p110δ)w a ss h o w nt op l a y
a crucial role in the development, differentiation, and
antigen receptor-induced proliferation of mature B cells
[35,36], and inhibition of p110δ attenuates allergic air-
way inflammation and AHR in a murine asthma model
[35,37]. In addition, IL-4 and IL-13 are important in
directing B cell growth, differentiation, and secretion of
IgE [38]. However, IFN-g released from Th1 cells prefer-
entially directs B cell switching of IgM to IgG2a and
IgG3 in mice [39,40]. HDME (3~30 μmol/kg, p.o.)
herein dose-dependently and significantly enhanced
total IgG2a level in the serum and suppressed total and
OVA-specific IgE levels in the BALF and serum of sen-
sitized and challenged mice, suggesting that HDME has
immunoregulatory and antiallergic asthmatic effects.
In the present results, HDME selectively inhibited
PDE4 activity with the IC50 and Ki values of 3.0 and 2.1
μM, respectively. Selective PDE4 inhibitors specifically
prevent the hydrolysis of cAMP, a 3’,5’-cyclic nucleotide,
and therefore have broad anti-inflammatory effects such
as inhibition of cell trafficking and of cytokine and che-
mokine release from inflammatory cells. The increased
cAMP levels induced by these selective PDE4 inhibitors
subsequently activate cAMP-dependent protein kinase
which may phosphorylate and inhibit myosin light-chain
kinase, thus inhibiting contractions [41]. The precise
mechanism through which relaxation is produced by
this second-messenger pathway is not known, but it
may result from decreased intracellular Ca
2+ ([Ca
2+]i).
The decrease in [Ca
2+]i may be due to reduced influx of
Ca
2+, enhanced Ca
2+ uptake into the sarcoplasmic reti-
cula, or enhanced Ca
2+ extrusion through cell mem-
branes [41]. Thus selective PDE4 inhibitors may have
bronchodilatory effects. The second-generation PDE4
inhibitors, cilomilast and roflumilast, have reached the
clinical trial stage and exhibit some beneficial effects in
treating asthma and COPD [42]. The effectiveness of
these PDE4 inhibitors may be limited by their clinical
potency when using doses that have minimal adverse
effects such as headaches, diarrhea, nausea, and abdom-
inal pain. The PDE4H/PDE4L ratios of cilomilast and
roflumilast were respectively reported to be 117.8 nM/
120 nM (1), and 2.4 nM/0.8 nM (3) [21,43], which are
considerably greater than that (0.01~0.001) of rolipram
[7]. Owing to its adverse effects or lack of efficacy, cilo-
milast was discontinued for use against asthma after
phase II clinical trials in 2003 [42]. In terms of tolerabil-
ity over 6 months with 15 mg twice daily for COPD in a
phase III study, cilomilast was reported to be associated
with higher frequencies of diarrhea and nausea than a
placebo [42]. Roflumilast was evaluated for asthma and
COPD in phase III clinical trials, and was reported to
reduce those adverse effects after longer-term treatment
at 0.5 mg once daily [42]. Roflumilast, compared to a
placebo, was reported to significantly improve the mean
pre- and post-bronchodilator forced expiratory volumes
in 1 s (FEV1) in patients with moderate-to-severe
COPD. However, nausea, diarrhea, weight loss, and
headaches were more frequent in patients in the roflu-
milast group. These adverse events were associated with
increased patient withdrawal [44,45]. Recently, roflumi-
last was approved by the European Commission as an
add-on to bronchodilator therapy for maintenance treat-
ment of severe COPD associated with chronic bronchitis
in adults with a history of frequent exacerbations. How-
ever, the US Food and Drug Administration voted
against using roflumilast to treat COPD. The PDE4H/
PDE4L r a t i oo fA W D1 2 - 2 8 1 ,a n o t h e rs e l e c t i v eP D E 4
inhibitor, was reported to be 104 nM/9.7 nM (approxi-
mately 11) [46]. AWD 12-281 was undergoing clinical
development phase IIa trials for COPD, and was
reported to be a unique potential drug for the topical
treatment of asthma and COPD [47]. AWD 12-281 was
reported to be a very promising drug candidate for
treating lung inflammation when administered by inha-
lation and for treating atopic dermatitis [48]. However,
AWD-12-281 was also discontinued in clinical trials for
both asthma and COPD owing to a lack of efficacy
[49,50]. Many compounds that are in development will
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emetic liability is reduced [51], although inhaled
GSK256066 demonstrated efficacy in trials in asthma
[52] and oral apremilast was clinically reported to be
effective for treating severe plaque-type psoriasis [53].
PDE4 subtypes (A~D) may be considered for drug
development of new PDE4 inhibitors. PDE4D inhibition
in non-target tissues promotes emesis, since PDE4D
knock-out mice showed reduction of xylazine/ketamine-
triggered anesthesia which is used as a surrogate marker
for emesis in mice, a non-vomiting species [13].
Recently, small-molecule allosteric modulators of
PDE4D that do not completely inhibit enzymatic activity
were reported to reduce emesis and have therapeutic
benefits of a brain distribution, for such entities as Alz-
heimer’sd i s e a s e ,H u n t i n g t o n ’s disease, schizophrenia,
and depression [54]. In contrast to PDE4D, selective
inhibition of PDE4A and/or PDE4B in proinflammatory
and immune cells is believed to evoke the therapeuti-
cally desired effects of these drugs [55]. Cilomilast has a
higher potency for PDE4D compared to PDE4A and
PDE4B, while roflumilast is non-selective for these four
PDE4 subtypes with similar degrees of inhibition [56].
There is no literature about AWD 12-281’s inhibition of
PDE4 subtypes until now. However, whether HDME
selectively inhibits the PDE4 subtype also needs to be
further investigated.
In the present results, the PDE4H/PDE4L ratio of
HDME was calculated to be 35.5, which is considerably
greater than that of AWD 12-281. In addition, HDME
did not influnce xylazine/ketamine-induced anesthesia.
However, rolipram, a selective PDE4 inhibitor, reversed
the anesthesia. The reversing effect may occur through
presynaptic a2-adrenoceptor inhibition [57], because
MK-912, an a2-adrenoceptor antagonist, was reported
to reverse xylazine/ketamine-induced anesthesia in rats
[12] and trigger vomiting in ferrets [57]. In contrast, clo-
nidine, an a2-adrenoceptor agonist, prevented emesis
induced by PDE4 inhibitors in ferrets [57]. The present
results also suggest that HDME may have few or no
adverse effects, such as nausea, vomiting, and gastric
hypersecretion.
Conclusions
In conclusion, HDME exerted anti-inflammatory effects,
including suppression of AHR, and reduced expressions
Figure 9 Mechanisms of action of HDME. HDME selectively inhibits PDE4 activities and results in an increase in cAMP, which activates cAMP-
dependent protein kinase (PKA) and increases calcium extrusion from the intracellular space and uptake to sarcoplasmic reticula (SR). Therefore,
HDME largely decreases the concentration of intracellular calcium ([Ca
2+]i) and results in bronchodilatation. The increase in cAMP also has anti-
inflammatory and immunoregulatory effects. AC, adenylate cyclase; Th, T-helper cells; Ig, immunoglobulin; IL, interleukin; IFN, interferon; TNF,
tumor necrosis factor. Up and down arrows respectively indicate increases and decreases.
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m o d e l ,w h i c ha p p e a r st ob es u i t a b l ef o rs t u d y i n gt h e
effects of drugs on atypical asthma and COPD, and for
screening those on typical asthma. Its mechanisms are
summarized in Figure 9. However, HDME did not influ-
nce xylazine/ketamine-induced anesthesia. Thus, HDME
may have the potential for use in treating typical and
atypical, at least in part, asthma, and COPD.
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